USFDA okays amlodipine oral suspension to treat hypertension in paediatric patients

USFDA okays amlodipine oral suspension to treat hypertension in paediatric patients

Azurity Pharmaceuticals announced that the USFDA has approved amlodipine (Katerzia) Oral Suspension, 1 mg/mL, the first and only FDA-approved amlodipine oral suspension.

Katerzia is indicated for the treatment of hypertension in adults and paediatric patients 6 years of age and older and coronary artery disease in adults.

The drug formulation offers a ready-to-use oral suspension for children 6 years of age and older that require or prefer an oral liquid option of amlodipine.

Katerzia will be readily available through an extensive network of pharmacies and a qualified mail order service, the company said in a news release.

Azurity Pharmaceuticals is a privately-held, specialty pharmaceutical company formed by the acquisition of Silvergate Pharmaceuticals, Inc. by CutisPharma, Inc., in May 2019.

Straight Talk

View More